| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14656566.2016.1258059 |
| P698 | PubMed publication ID | 27835047 |
| P50 | author | Laurence Albiges | Q54553347 |
| Bernard Escudier | Q54553923 | ||
| P2093 | author name string | Julie C Lougheed | |
| P2860 | cites work | Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer | Q27853086 |
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 | ||
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma | Q33409916 | ||
| Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy | Q34007924 | ||
| Cabozantinib in progressive medullary thyroid cancer | Q34185084 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma | Q34293726 | ||
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial | Q34650664 | ||
| Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. | Q34658095 | ||
| The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study | Q35561464 | ||
| c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma | Q36551653 | ||
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer | Q36822111 | ||
| The VHL/HIF axis in clear cell renal carcinoma | Q36872295 | ||
| In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer | Q37403891 | ||
| Targeted therapies for renal cell carcinoma: review of adverse event management strategies | Q37974894 | ||
| A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 | ||
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma | Q38835745 | ||
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. | Q38859789 | ||
| Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth | Q39472261 | ||
| Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. | Q41099660 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. | Q45945576 | ||
| Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites. | Q45950959 | ||
| Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults | Q46252268 | ||
| Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. | Q52985746 | ||
| Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. | Q54362470 | ||
| Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. | Q55060584 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2499-2504 | |
| P577 | publication date | 2016-11-11 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Cabozantinib for the treatment of renal cell carcinoma | |
| P478 | volume | 17 |
| Q57481747 | Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma |
| Q52661758 | Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. |
| Q49887893 | Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities |
Search more.